請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78527完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 蔡丰喬 | |
| dc.contributor.author | Yuan-Yuan Feng | en |
| dc.contributor.author | 馮圓媛 | zh_TW |
| dc.date.accessioned | 2021-07-11T15:02:06Z | - |
| dc.date.available | 2024-08-29 | |
| dc.date.copyright | 2019-08-29 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-19 | |
| dc.identifier.citation | L. A.Torre, F.Bray, R. L.Siegel, J.Ferlay, J.Lortet-Tieulent, and A.Jemal, “Global cancer statistics, 2012.,” CA. Cancer J. Clin., 2015.
F.Bray, J.Ferlay, I.Soerjomataram, R. L.Siegel, L. A.Torre, and A.Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.,” CA. Cancer J. Clin., 2018. “European Association for the Study of the Liver: EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma,” J. Hepatol., 2012. J. M.Llovet et al., “Hepatocellular carcinoma.,” Nat. Rev. Dis. Prim., 2016. Y.Xie, “Hepatitis B virus-associated hepatocellular carcinoma,” in Advances in Experimental Medicine and Biology, 2017. M. C.Kew, “Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma.,” J. Gastroenterol. Hepatol., vol. 26 Suppl 1, pp. 144–52, Jan.2011. M. A.Feitelson and L. X.Duan, “Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma.,” Am. J. Pathol., 1997. C. M.Kim, K.Koike, I.Saito, T.Miyamura, and G.Jay, “HBx gene of hepatitis B virus induces liver cancer in transgenic mice.,” Nature, vol. 351, no. 6324, pp. 317–20, May1991. P.Boffetta and P.Hainaut, Encyclopedia of cancer, 3rd ed., vol. 34, no. 10. Academic Press, 2013. Q.Cai, Z.Yuan, and K.Lan, Infectious Agents Associated Cancers: Epidemiology and Molecular Biology, vol. 1018. 2017. F.Zoulim, J.Saputelli, and C.Seeger, “Woodchuck hepatitis virus X protein is required for viral infection in vivo.,” J. Virol., 1994. V.V.Keasler, A. J.Hodgson, C. R.Madden, and B. L.Slagle, “Enhancement of Hepatitis B Virus Replication by the Regulatory X Protein In Vitro and In Vivo,” J. Virol., 2007. A.Decorsière et al., “Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.,” Nature, vol. 531, no. 7594, pp. 386–9, Mar.2016. D. E.Clapham, “Calcium Signlaing,” Cell, 2007. M. J.Berridge, “Calcium signalling remodelling and disease,” Biochem. Soc. Trans., 2012. N.Yang et al., “Blockade of store-operated Ca(2+) entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover.,” Cancer Lett., vol. 330, no. 2, pp. 163–9, Apr.2013. X.Geng et al., “Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans,” Proc. Natl. Acad. Sci., 2012. X.Geng et al., “Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction,” Proc. Natl. Acad. Sci. U. S. A., vol. 109, no. 45, pp. 18471–18476, Nov.2012. M.Driscoll and B.Gerstbrein, “Dying for a cause: invertebrate genetics takes on human neurodegeneration.,” Nat. Rev. Genet., vol. 4, no. 3, pp. 181–94, Mar.2003. G.Natoli et al., “Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX.,” Oncogene, vol. 9, no. 10, pp. 2837–43, Oct.1994. N. P.Klein and R. J.Schneider, “Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras.,” Mol. Cell. Biol., vol. 17, no. 11, pp. 6427–36, Nov.1997. N. P.Klein, M. J.Bouchard, L. H.Wang, C.Kobarg, and R. J.Schneider, “Src kinases involved in hepatitis B virus replication.,” EMBO J., vol. 18, no. 18, pp. 5019–27, Sep.1999. S.Lev et al., “Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions.,” Nature, vol. 376, no. 6543, pp. 737–45, Aug.1995. H.Friberg, M.Ferrand-Drake, F.Bengtsson, A. P.Halestrap, and T.Wieloch, “Cyclosporin A, But Not FK 506, Protects Mitochondria and Neurons against Hypoglycemic Damage and Implicates the Mitochondrial Permeability Transition in Cell Death,” J. Neurosci., vol. 18, no. 14, pp. 5151–5159, Jul.1998. D. A.Cox, L.Conforti, N.Sperelakis, and M. A.Matlib, “Selectivity of inhibition of Na(+)-Ca2+ exchange of heart mitochondria by benzothiazepine CGP-37157.,” J. Cardiovasc. Pharmacol., vol. 21, no. 4, pp. 595–9, Apr.1993. R.Palty and I.Sekler, “The mitochondrial Na(+)/Ca(2+) exchanger.,” Cell Calcium, vol. 52, no. 1, pp. 9–15, Jul.2012. 蔡沛儒, “HBx對細胞鈣離子恆定影響之研究,” 國立臺灣大學, 2016. D.HANAHAN, “ScienceDirect - Cell : The Hallmarks of Cancer,” Cell, 2000. L.Moore, T.Chen, H. R.Knapp, and E. J.Landon, “Energy-dependent calcium sequestration activity in rat liver microsomes.,” J. Biol. Chem., vol. 250, no. 12, pp. 4562–8, Jun.1975. T. B.Rogers, G.Inesi, R.Wade, and W. J.Lederer, “Use of thapsigargin to study Ca2+ homeostasis in cardiac cells.,” Biosci. Rep., vol. 15, no. 5, pp. 341–9, Oct.1995. R. Y.Tsien, “A non-disruptive technique for loading calcium buffers and indicators into cells,” Nature, 1981. L. B.Cohen et al., “Changes in axon fluorescence during activity: Molecular probes of membrane potential,” J. Membr. Biol., 1974. L.C and H.TE., “Characterization of ionomycin as a calcium ionophore.,” J Biol Chem., vol. 253, no. 17, pp. 5892–4., 1978. T. M.Brand, M.Iida, C.Li, and D. L.Wheeler, “The nuclear epidermal growth factor receptor signaling network and its role in cancer.,” Discov. Med., 2011. C. W.Taylor and S. C.Tovey, “IP(3) receptors: toward understanding their activation.,” Cold Spring Harb. Perspect. Biol., vol. 2, no. 12, p. a004010, Dec.2010. T.Jayaraman, K.Ondrias, E.Ondriasová, and A. R.Marks, “Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation.,” Science, vol. 272, no. 5267, pp. 1492–4, Jun.1996. Calcium: The Molecular Basis of Calcium Action in Biology and Medicine. 2011. Y.-J.Chen et al., “Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells.,” Evid. Based. Complement. Alternat. Med., vol. 2013, p. 682380, 2013. D. A. E.Cross et al., “AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.,” Cancer Discov., vol. 4, no. 9, pp. 1046–61, Sep.2014. L. C.Crowley, A. P.Scott, B. J.Marfell, J. A.Boughaba, G.Chojnowski, and N. J.Waterhouse, “Measuring Cell Death by Propidium Iodide Uptake and Flow Cytometry.,” Cold Spring Harb. Protoc., vol. 2016, no. 7, 2016. P.Pozarowski and Z.Darzynkiewicz, “Analysis of Cell Cycle by Flow Cytometry,” in Checkpoint Controls and Cancer, A. H.Schönthal, Ed.Humana Press, 2004, pp. 301–311. H. R.Luo et al., “Akt as a mediator of cell death,” Proc. Natl. Acad. Sci., 2003. Z.Lu and S.Xu, “ERK1/2 MAP kinases in cell survival and apoptosis.,” IUBMB Life, vol. 58, no. 11, pp. 621–31, Nov.2006. E. C. C.Cheung and R. S.Slack, “Emerging role for ERK as a key regulator of neuronal apoptosis.,” Sci. STKE, vol. 2004, no. 251, p. PE45, Sep.2004. W.Woessmann, X.Chen, and A.Borkhardt, “Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines.,” Cancer Chemother. Pharmacol., vol. 50, no. 5, pp. 397–404, Nov.2002. E. J.Lowenstein et al., “The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.,” Cell, 1992. I.Vivanco and C. L.Sawyers, “The phosphatidylinositol 3-kinase-AKT pathway in humancancer,” Nat. Rev. Cancer, 2002. J.Bromberg, “Stat proteins and oncogenesis.,” J. Clin. Invest., vol. 109, no. 9, pp. 1139–42, May2002. R. L.Patterson, D. B.vanRossum, N.Nikolaidis, D. L.Gill, and S. H.Snyder, “Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling.,” Trends Biochem. Sci., vol. 30, no. 12, pp. 688–97, Dec.2005. A.Tomar and D. D.Schlaepfer, “A PAK-Activated Linker for EGFR and FAK,” Developmental Cell. 2010. G. M. M.Stephenson and D. G.Stephenson, “Endogenous MLC2 phosphorylation and Ca2+-activated force in mechanically skinned skeletal muscle fibres of the rat,” Pflügers Arch. Eur. J. Physiol., 1993. J.Nakai, M.Ohkura, and K.Imoto, “A high signal-to-noise ca2+ probe composed of a single green fluorescent protein,” Nat. Biotechnol., 2001. J. S.Marvin et al., “Crystal Structures of the GCaMP Calcium Sensor Reveal the Mechanism of Fluorescence Signal Change and Aid Rational Design,” J. Biol. Chem., 2008. J. J.Ding, A. F.Luo, L. Y.Hu, D. C.Wang, and F.Shao, “Structural basis of the ultrasensitive calcium indicator GCaMP6,” Sci. China Life Sci., 2014. N.Schek, R.Bartenschlager, C.Kuhn, and H.Schaller, “Phosphorylation and rapid turnover of hepatitis B virus X-protein expressed in HepG2 cells from a recombinant vaccinia virus.,” Oncogene, 1991. F.Giovanna, F.Bortolotti, and D.Francesco, “Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors,” Journal of Hepatology. 2008. Y.Wang, S. H.Lau, J. S.-T.Sham, M.-C.Wu, T.Wang, and X.-Y.Guan, “Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis.,” Oncogene, vol. 23, no. 1, pp. 142–8, Jan.2004. N.-F.Ma et al., “COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis.,” Clin. Cancer Res., vol. 14, no. 16, pp. 5061–8, Aug.2008. H.Tu et al., “Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues.,” Cancer Res., vol. 61, no. 21, pp. 7803–10, Nov.2001. D. X.Yin, L.Zhu, and R. T.Schimke, “Tetracycline-controlled gene expression system achieves high-level and quantitative control of gene expression.,” Anal. Biochem., vol. 235, no. 2, pp. 195–201, Mar.1996. B. L.Slagle, O. M.Andrisani, M. J.Bouchard, C. G. L.Lee, J.-H. J.Ou, and A.Siddiqui, “Technical standards for hepatitis B virus X protein (HBx) research.,” Hepatology, vol. 61, no. 4, pp. 1416–24, Apr.2015. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78527 | - |
| dc.description.abstract | 在全球，肝癌的致死率居高不下，其中在原發性肝癌中，以肝細胞癌(Hepatocellular carcinoma，HCC)佔了最高的比例，為75-85%，而慢性B型肝炎病毒(Hepatitis B virus，HBV)感染為肝細胞癌的主因。然而，慢性HBV感染導致肝細胞癌的原因仍是個未解的難題。在過去的研究中，由於B型肝炎病毒X蛋白(Hepatitis B virus X protein，HBx)與HCC有緊密的關聯，例如：在與HBV感染相關的HCC病人上可以偵測到HBx的表現，以及表現HBx的基因轉殖鼠有較高生成肝腫瘤的發生率，同時，HBx也曾被報導與HBV的複製及轉錄相關，因此HBx是科學家們研究肝細胞癌機制的標的之一。除此之外，HBx與鈣之間有所連結：HBx會與和B細胞淋巴瘤-2 (B-cell lymphoma 2，Bcl-2)，以及線蟲中與此蛋白同源的細胞死亡異常基因9 (Cell death abnormally gene 9，CED-9)蛋白進行交互作用來提升細胞內鈣離子的訊號，同時，鈣離子訊號的改變也會影響HBx所促進的HBV複製現象。由以上的發現，推測HBx或許會藉由改變鈣離子訊號傳遞，並進而導致肝癌。關於HBx對於鈣離子恆定的影響，由實驗室的其他同仁進行探討中，本篇研究將定睛於解答：鈣離子訊息傳遞是否在HBx所誘導的事件中，扮演了不可或缺的角色之問題。研究的策略為：(1)建立可信賴的平台闡述HBx所造成的影響；(2)嘗試找到操縱鈣離子傳遞訊號及在過程中精確地測量鈣濃度的方式，確保實驗結果與所建立實驗環境之對應；(3)皆完備後，嘗試回答研究目的。
本篇研究有兩個初步的發現：HBx使得細胞數目減少，以及HBx與上皮生長因子受體(Epidermal growth factor receptor，EGFR)之間可能有交互作用。我們發現使用慢病毒感染使得HepG2人類肝細胞癌肝上皮細胞表現HBx時，將使得細胞數量下降，並在這個發現的基礎上，嘗試使用Thapsigargin、EGTA等鈣離子試劑觀測其對於HBx組與控制組之間細胞數量的影響，我們觀察到：HBx對於Thapsigargin的IC50沒有影響，但當創造高鈣離子濃度的環境時，HBx似乎會導致細胞數量減少的程度下降。因此，我們計畫以更精確的平台，如Cell death assay和Cell cycle assay來觀測，期許可以獲得更清晰的結果。第二個初步的發現，則是由於在兩種細胞株，HepG2人類肝細胞癌肝上皮細胞與FL83B小鼠肝細胞上觀察到HBx似乎會降低EGF促使細胞增加的效果，使我們猜測HBx所造成的細胞數目下降可能依賴於EGFR信號通路，同時也因為EGFR的活化與鈣離子訊號傳遞之間有所關聯，因此進一步探討HBx對於EGFR之表現及其下游信號通路的影響，實驗的結果說明HBx所造成細胞數目的下降應與EGFR信號通路無關，而HBx會增強细胞外調節蛋白激酶(Extracellular regulated protein kinases，ERK)的磷酸化訊號，以及縮短蛋白激酶B (Protein kinase B，PKB /Akt)磷酸化訊號的持續時間。目前正在嘗試以GCaMP6s作為鈣指示劑，比較有無HBx是否會影響加入EGF之後鈣離子訊號的變化。 盼望在未來當平台的建立更加成熟，也找到適當的方式調控鈣離子訊號時，能精進現今的實驗結果，一步一步地朝著解答肝細胞癌機制之方向前進。 | zh_TW |
| dc.description.abstract | Hepatic cancer is one of the leading causes of cancer mortality globally. Hepatocellular carcinoma (HCC) accounts for 75-85% of primary hepatic cancer cases. Among various risk factors, the infection of hepatitis B virus (HBV) is the main cause of HCC. However, the mechanism of HBV-related HCC remains unknown. Previous studies have shown that an HBV-encoded protein: hepatitis B virus X protein (HBx), is tightly correlated with HCC because HBx expression was detected in most HBV-related HCC, and similarly, high incidences of liver tumors were found in transgenic mice expressing HBx. Besides, HBx was reported to regulate HBV replication and transcription, so it becomes a key to reveal possible resolutions to HCC. Additionally, it was found that Bcl-2 (and its homologue in Caenorhabditis elegans CED-9) was targeted by HBx to elevate intracellular calcium signaling. Furthermore, alteration of cytosolic calcium changed HBx-mediated HBV replication. From the above findings, we assumed that HBx may lead to HCC by regulating calcium signaling. The part of HBx influence on calcium signaling was investigated by our laboratory colleagues. Therefore, the aim of this study is to find out whether HBx-related effects are calcium-dependent. The strategy of this study includes three stages. (1) To build up reliable assays illustrating HBx effects. (2) To find out good ways to manipulate calcium signaling and calculate calcium concentration precisely during the experiment. (3) To observe the changes of HBx-induced effects influenced by calcium manipulation.
Our two preliminary findings were that the cell count in HBx-infected group was decreased compared to the control one and there might be an interaction between HBx and epidermal growth factor receptor (EGFR) signaling. To evaluate HBx-induced cell number reduction, we used calcium reagents, such as Thapsigargin and EGTA, to observe their effect on the cell count of HBx and control group. We found that HBx has no impact on IC50 of Thapsigargin, but it seemed that HBx caused smaller extent of cell number reduction under higher calcium concentration. Thus, we will recruit cell death and cell cycle assay to further elucidate its underlying mechanisms. The second preliminary finding was that HBx seemed to reduce the effect of EGF-related cell number addition on two cell lines, HepG2 and FL83B. We thus proposed that HBx-induced cell number reduction might rely on EGFR signaling. Toghther with the known association between EGFR signaling and calcium activation, we decided to explore HBx effect on EGFR expression and its downstream signaling pathways. The result revealed that the cell count decrease caused by HBx was unrelated to EGFR signaling and that HBx enhanced the signal of phosphorylated ERK and shortened the duration of AKT activation. Currently, we are using GCaMP6s as a calcium indicator to compare the calcium signaling between HBx and control group after EGF treatment. In the future, we will keep optimizing above HBx-related assays and calcium measurement to reach a deep clarification of HBx-induced events and their variation influenced by calcium signaling alteration, so the goal to uncover the mechanism of HBV-related HCC could be achieved very soon. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T15:02:06Z (GMT). No. of bitstreams: 1 ntu-108-R06443007-1.pdf: 4046557 bytes, checksum: 425713d22fdf696db21c26342f519864 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 口試委員會審定書 1
誌謝 2 中文摘要 3 Abstract 5 目錄 8 圖目錄 11 表目錄 12 第一章、緒論 13 1. 研究動機 13 1-1 研究背景 13 1-2 研究目的 18 1-3 研究策略 19 第二章、材料與方法 20 1. 細胞培養 20 2. 所用質體簡介 20 3. 轉染質體 (Plasmid DNA transfection) 21 4. 慢病毒製備及感染(Lentivirus preparation and infection) 21 5. 穩定表達細胞系(Stable cell line)製備 22 6. 細胞存活率實驗(Cell viability assay) 22 7. 蛋白質萃取(Protein extraction)與西方墨點法(Western blotting) 23 8. 以PI (Propidium iodine)染色觀測細胞死亡(Cell death)及細胞週期(Cell cycle) 26 9. 鈣離子成像(Calcium Imaging) 27 第三章、結果 29 1. 實驗平台的建立 29 2. HBx導致細胞數目的下降 31 3. 觀測當表現HBx，改變鈣離子於cell viability assay的展現與控制組之差異 33 4. HBx與EGFR之間關聯性的探討 40 第四章、討論與結論 52 1. 以流式細胞術(Flow cytometry)驗證HBx與細胞數量之間的關聯 52 2. HBx於EGFR上的效應可能非展現於促使細胞死亡的表現上 54 3. HBx對於給予EGF後pSTAT3和pMLC2被激發的情形沒有特別的影響 54 4. 難以使用AM類藥品製造所設想的鈣離子環境 56 5. 使用GCaMP6s探討加入EGF後鈣離子訊號的變化 57 6. 實驗材料選用及方向之探討 60 7. 由觀測Stable cell line的生長所激發之未來研究方向 62 8. 所選用Cell viability assay平台之檢討及其中所遇之困難 63 第五章、參考資料 64 第六章、附錄 71 1. Matlab® 程式碼 71 2. 質體圖譜 93 | |
| dc.language.iso | zh-TW | |
| dc.subject | 上皮生長因子受體 | zh_TW |
| dc.subject | 肝細胞癌 | zh_TW |
| dc.subject | B型肝炎病毒 | zh_TW |
| dc.subject | HBx | zh_TW |
| dc.subject | 鈣離子 | zh_TW |
| dc.subject | Epithelial growth factor receptor (EGFR) | en |
| dc.subject | Hepatocellular carcinoma (HCC) | en |
| dc.subject | Hepatitis B virus (HBV) | en |
| dc.subject | Hepatitis B virus X protein (HBx) | en |
| dc.subject | Ca2+ | en |
| dc.title | 鈣離子訊號傳遞在HBx蛋白誘導事件中的重要性 | zh_TW |
| dc.title | The importance of Ca2+ signaling in HBx-induced events | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 葉秀慧,張偉嶠,黃偉謙 | |
| dc.subject.keyword | 肝細胞癌,B型肝炎病毒,HBx,鈣離子,上皮生長因子受體, | zh_TW |
| dc.subject.keyword | Hepatocellular carcinoma (HCC),Hepatitis B virus (HBV),Hepatitis B virus X protein (HBx),Ca2+,Epithelial growth factor receptor (EGFR), | en |
| dc.relation.page | 95 | |
| dc.identifier.doi | 10.6342/NTU201903770 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-08-19 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| dc.date.embargo-lift | 2024-08-29 | - |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-R06443007-1.pdf 未授權公開取用 | 3.95 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。